Market Closed -
Nasdaq Copenhagen
10:59:38 2024-05-02 EDT
|
5-day change
|
1st Jan Change
|
873.1
DKK
|
-2.74%
|
|
-2.04%
|
+25.07%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
909,347
|
986,612
|
1,674,992
|
2,118,803
|
3,112,331
|
3,878,794
|
-
|
-
|
Enterprise Value (EV)
1 |
898,355
|
984,211
|
1,684,152
|
2,121,013
|
3,109,107
|
3,932,736
|
3,891,157
|
3,852,312
|
P/E ratio
|
23.6
x
|
23.7
x
|
35.4
x
|
38.4
x
|
37.5
x
|
37.9
x
|
31
x
|
26.2
x
|
Yield
|
2.16%
|
2.13%
|
1.41%
|
1.32%
|
1.35%
|
1.4%
|
1.62%
|
1.88%
|
Capitalization / Revenue
|
7.45
x
|
7.77
x
|
11.9
x
|
12
x
|
13.4
x
|
13.5
x
|
11.2
x
|
9.68
x
|
EV / Revenue
|
7.36
x
|
7.75
x
|
12
x
|
12
x
|
13.4
x
|
13.7
x
|
11.2
x
|
9.61
x
|
EV / EBITDA
|
15.5
x
|
16.4
x
|
26
x
|
25.8
x
|
27.8
x
|
27.9
x
|
22.5
x
|
18.9
x
|
EV / FCF
|
26.1
x
|
34.5
x
|
57.4
x
|
37
x
|
45.5
x
|
62.9
x
|
39.6
x
|
31.8
x
|
FCF Yield
|
3.83%
|
2.9%
|
1.74%
|
2.7%
|
2.2%
|
1.59%
|
2.52%
|
3.14%
|
Price to Book
|
15.8
x
|
15.8
x
|
24
x
|
25.6
x
|
29.4
x
|
26.3
x
|
20.1
x
|
15.5
x
|
Nbr of stocks (in thousands)
|
4,703,720
|
4,624,923
|
4,557,801
|
4,517,704
|
4,458,288
|
4,442,554
|
-
|
-
|
Reference price
2 |
193.3
|
213.3
|
367.5
|
469.0
|
698.1
|
873.1
|
873.1
|
873.1
|
Announcement Date
|
20-02-05
|
21-02-03
|
22-02-02
|
23-02-01
|
24-01-31
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
122,021
|
126,946
|
140,800
|
176,954
|
232,261
|
287,248
|
346,767
|
400,877
|
EBITDA
1 |
58,144
|
59,879
|
64,669
|
82,171
|
111,987
|
141,140
|
172,854
|
203,934
|
EBIT
1 |
52,483
|
54,126
|
58,644
|
74,809
|
102,574
|
129,360
|
158,540
|
187,697
|
Operating Margin
|
43.01%
|
42.64%
|
41.65%
|
42.28%
|
44.16%
|
45.03%
|
45.72%
|
46.82%
|
Earnings before Tax (EBT)
1 |
48,553
|
53,130
|
59,080
|
69,062
|
104,674
|
129,953
|
158,028
|
186,209
|
Net income
1 |
38,951
|
42,138
|
47,757
|
55,525
|
83,683
|
103,284
|
125,295
|
147,126
|
Net margin
|
31.92%
|
33.19%
|
33.92%
|
31.38%
|
36.03%
|
35.96%
|
36.13%
|
36.7%
|
EPS
2 |
8.190
|
9.005
|
10.37
|
12.22
|
18.62
|
23.02
|
28.15
|
33.33
|
Free Cash Flow
1 |
34,451
|
28,565
|
29,319
|
57,362
|
68,326
|
62,483
|
98,223
|
120,968
|
FCF margin
|
28.23%
|
22.5%
|
20.82%
|
32.42%
|
29.42%
|
21.75%
|
28.33%
|
30.18%
|
FCF Conversion (EBITDA)
|
59.25%
|
47.7%
|
45.34%
|
69.81%
|
61.01%
|
44.27%
|
56.82%
|
59.32%
|
FCF Conversion (Net income)
|
88.45%
|
67.79%
|
61.39%
|
103.31%
|
81.65%
|
60.5%
|
78.39%
|
82.22%
|
Dividend per Share
2 |
4.175
|
4.550
|
5.200
|
6.200
|
9.400
|
12.26
|
14.11
|
16.38
|
Announcement Date
|
20-02-05
|
21-02-03
|
22-02-02
|
23-02-01
|
24-01-31
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
35,622
|
38,333
|
42,301
|
41,265
|
45,566
|
48,092
|
53,367
|
54,300
|
58,731
|
65,863
|
65,349
|
67,793
|
72,839
|
80,523
|
82,844
|
EBITDA
1 |
16,598
|
15,716
|
20,797
|
20,027
|
22,225
|
19,122
|
26,726
|
26,065
|
29,438
|
29,758
|
34,760
|
33,006
|
38,352
|
37,504
|
44,556
|
EBIT
1 |
15,249
|
13,634
|
19,147
|
18,391
|
20,184
|
17,087
|
25,007
|
23,888
|
26,913
|
26,766
|
31,846
|
30,532
|
33,553
|
34,716
|
40,691
|
Operating Margin
|
42.81%
|
35.57%
|
45.26%
|
44.57%
|
44.3%
|
35.53%
|
46.86%
|
43.99%
|
45.82%
|
40.64%
|
48.73%
|
45.04%
|
46.06%
|
43.11%
|
49.12%
|
Earnings before Tax (EBT)
1 |
15,112
|
13,113
|
17,919
|
16,795
|
18,032
|
16,316
|
24,737
|
24,254
|
28,063
|
27,620
|
31,918
|
31,128
|
32,621
|
34,289
|
40,814
|
Net income
1 |
12,119
|
10,892
|
14,210
|
13,318
|
14,405
|
13,592
|
19,814
|
19,428
|
22,478
|
21,963
|
25,407
|
24,407
|
26,611
|
27,471
|
30,506
|
Net margin
|
34.02%
|
28.41%
|
33.59%
|
32.27%
|
31.61%
|
28.26%
|
37.13%
|
35.78%
|
38.27%
|
33.35%
|
38.88%
|
36%
|
36.53%
|
34.12%
|
36.82%
|
EPS
2 |
2.635
|
2.380
|
3.110
|
2.930
|
3.170
|
3.010
|
4.390
|
4.315
|
5.000
|
4.910
|
5.680
|
5.533
|
5.861
|
5.887
|
15.06
|
Dividend per Share
2 |
-
|
3.450
|
-
|
2.125
|
-
|
4.075
|
-
|
3.000
|
-
|
6.400
|
2.932
|
3.491
|
2.932
|
5.191
|
3.714
|
Announcement Date
|
21-11-03
|
22-02-02
|
22-04-29
|
22-08-03
|
22-11-02
|
23-02-01
|
23-05-04
|
23-08-10
|
23-11-02
|
24-01-31
|
24-05-02
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
9,160
|
2,210
|
-
|
53,942
|
12,363
|
-
|
Net Cash position
1 |
10,992
|
2,401
|
-
|
-
|
3,224
|
-
|
-
|
26,482
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.1416
x
|
0.0269
x
|
-
|
0.3822
x
|
0.0715
x
|
-
|
Free Cash Flow
1 |
34,451
|
28,565
|
29,319
|
57,362
|
68,326
|
62,483
|
98,223
|
120,968
|
ROE (net income / shareholders' equity)
|
71.2%
|
69.7%
|
71.2%
|
72%
|
88.1%
|
82.2%
|
92.1%
|
84.6%
|
ROA (Net income/ Total Assets)
|
33%
|
31.2%
|
28.1%
|
25.5%
|
30.1%
|
27.8%
|
29%
|
31.2%
|
Assets
1 |
118,191
|
135,267
|
169,715
|
217,883
|
277,872
|
371,139
|
431,598
|
471,643
|
Book Value Per Share
2 |
12.20
|
13.50
|
15.30
|
18.30
|
23.80
|
33.20
|
43.50
|
56.30
|
Cash Flow per Share
2 |
9.840
|
11.10
|
11.90
|
17.40
|
24.20
|
22.90
|
27.40
|
31.20
|
Capex
1 |
8,932
|
5,825
|
6,335
|
12,146
|
25,806
|
45,441
|
43,047
|
43,067
|
Capex / Sales
|
7.32%
|
4.59%
|
4.5%
|
6.86%
|
11.11%
|
15.82%
|
12.41%
|
10.74%
|
Announcement Date
|
20-02-05
|
21-02-03
|
22-02-02
|
23-02-01
|
24-01-31
|
-
|
-
|
-
|
Last Close Price
897.7
DKK Average target price
904.2
DKK Spread / Average Target +0.72% Consensus |
1st Jan change
|
Capi.
|
---|
| +25.07% | 571B | | +29.68% | 699B | | -4.35% | 364B | | +17.65% | 326B | | +3.77% | 286B | | +14.68% | 236B | | +4.71% | 198B | | -12.43% | 194B | | -3.79% | 154B | | -3.34% | 149B |
Other Pharmaceuticals
|